Compare Vanguard Short Term Corporate Bond ETF (VCSH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Short Term Corporate Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 5.1× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Short Term Corporate Bond ETF for 52 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VCSH | XBI | |
|---|---|---|
Market Cap | $51.90B | $10.11B |
Volume | 2,892,221 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $80.20 | $169.55 |
52-Week Low | $77.03 | $104.99 |
Typical Hold Time | 52 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCSH trades at $77.30 with minimal daily movement (+0.04%). The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights VCSH's competitive 4.5-4.8% dividend yield and low 0.03% expense ratio, though credit spreads remain tight. The ETF's short 2.7-year duration provides some protection against rising rates.
VCSH offers stable income exposure to investment-grade corporate bonds but faces headwinds from tight credit spreads and limited price appreciation potential. The fund's low duration minimizes interest rate risk, making it suitable for conservative investors seeking yield above Treasury alternatives, though corporate credit risk remains a consideration in economic downturns.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
